Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for US$13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its US$74 billion deal for Celgene.
Celgene to sell psoriasis drug Otezla for US$13.4 billion to Amgen
